

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
09/927,408	08/10/2001	Volker Gerdts	9000-0058	6385	
23419	7590 10/15/2003		EXAM	EXAMINER	
COOLEY GODWARD, LLP			FOLEY, SHANON A		
3000 EL CAMINO REAL 5 PALO ALTO SQUARE			ART UNIT	PAPER NUMBER	
PALO ALTO, CA 94306		1648			
			DATE MAILED: 10/15/2003	· (

Please find below and/or attached an Office communication concerning this application or proceeding.

	(
	Application No.	Applicant(s)				
,	09/927,408	GERDTS ET AL.				
Office Action Summary	Examiner	Art Unit				
	Shanon Foley	1648				
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet	with the correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a rep If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statut - Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b). Status	136(a). In no event, however, may sly within the statutory minimum of the will apply and will expire SIX (6) Mee, cause the application to become	a reply be timely filed nirty (30) days will be considered timely. DNTHS from the mailing date of this communication. ABANDONED (35 U.S.C. § 133).				
1) Responsive to communication(s) filed on 10	<u>August 2001</u> .					
2a) This action is FINAL . 2b) ⊠ The	his action is non-final.					
 Since this application is in condition for allow closed in accordance with the practice under Disposition of Claims 						
4) Claim(s) 1-25 is/are pending in the application	n.					
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.	Claim(s) is/are objected to.					
8) Claim(s) <u>1-25</u> are subject to restriction and/or	election requirement.					
Application Papers						
9)☐ The specification is objected to by the Examine	er.					
10) The drawing(s) filed on is/are: a) acce	epted or b) objected to by	the Examiner.				
Applicant may not request that any objection to the						
11) The proposed drawing correction filed on		disapproved by the Examiner.				
If approved, corrected drawings are required in re						
12) The oath or declaration is objected to by the Ex	xaminer.					
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreig	n priority under 35 U.S.C	. § 119(a)-(d) or (f).				
a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documen	ts have been received in	Application No				
 3. Copies of the certified copies of the price application from the International But See the attached detailed Office action for a list 	ureau (PCT Rule 17.2(a))					
14) Acknowledgment is made of a claim for domest	tic priority under 35 U.S.C	C. § 119(e) (to a provisional application).				
a) ☐ The translation of the foreign language pro 15)☐ Acknowledgment is made of a claim for domes	i i					
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of	w Summary (PTO-413) Paper No(s) of Informal Patent Application (PTO-152)				

Application/Control Number: 09/927,408

Art Unit: 1648

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-8, 12-14, 24 and 25, drawn to a method of eliciting an immune response by administering a nucleic acid *in utero*, classified in class 424, subclass 278.1 and class 514, subclass 44.
- II. Claims 9-11 and 15-23, drawn to a method of eliciting an immune response by priming with a nucleic acid *in utero* and boosting at birth, classified in class 424, subclass 278.1.

If applicant elects this group, applicant is required to elect a boosting composition from A or B:

- A) the boosting composition is a nucleic acid (claims 10, 16, 19)
- B) the boosting composition is a subunit (claims 11, 17, 20)

Claims 9, 15, 18 and 21-23 are linking claims and will be examined upon the election of either A or B.

The inventions are distinct, each from the other because of the following reasons:

Inventions A and B are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are drawn to different molecules. The composition of A comprises nucleic acid residues while the composition of B comprises amino acid residues. Each of the molecules have

Application/Control Number: 09/927,408

Art Unit: 1648

different modes of operation, different functions and have different effects on the immune system. Therefore, each group is patentably distinct.

Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are drawn to treating different subjects. The subjects of group I are *in utero* while the population of subjects treated in group II have completed gestation and have a primed immune system to an antigen at birth. In addition, each of the methods require different method steps and compositions required to complete each method, resulting in different effects.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper. The search required for Group I is not required for Group II due to the different populations and divergent methods and compositions used to elicit an immune response. In addition, issues that may arise in examination of one group may differ.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Art Unit: 1648

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shanon Foley whose telephone number is (703) 308-3983. The examiner can normally be reached on M-F 9:00-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached on (703) 308-4027. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Shanon Foley